2,5-dimethyl-N-ethylaniline | 13519-76-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,5-dimethyl-N-ethylaniline
• 英文别名: N-ethyl-2,5-dimethyl-aniline；N-Aethyl-2,5-dimethyl-anilin；Aethyl-p-xylidin；(2,5-Dimethylphenyl)ethylamine；N-Aethyl-2,5-dimethyl-anilin；N-ethyl-2,5-dimethylaniline
• CAS: 13519-76-1
• 化学式: C₁₀H₁₅N
• mdl: MFCD03210690
• 分子量: 149.236
• InChiKey: OROYQHXCXXJBOP-UHFFFAOYSA-N

物化性质

• 沸点：
  221-224 °C
• 密度：
  0.944±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,5-dimethyl-N-ethylaniline 在 potassium fluoride 、 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 3,4,7,8-四甲基-1,10-菲罗啉 、 norbornene 、 K⁽¹⁺⁾*F₂H⁽¹⁺⁾ 、 双氧水 、 potassium hydrogencarbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 60.0h， 生成
  参考文献：
  名称：

  芳烃和苄型的C铱催化区域选择性硅烷化？仲胺指导的H键

  摘要：

  本文报道的是铱催化的苄胺芳族CH键和2 N-二烷基苯胺的苄基CH键的区域选择性甲硅烷基化反应。在该方法中，通过苄胺或苯胺与二乙基硅烷的脱氢偶联原位生成的（氢化）甲硅烷基胺在氨基的CH键γ处进行选择性甲硅烷基化。这种甲硅烷基化的产物适用于随后的氧化，卤化和交叉偶联反应，以递送苄胺和芳胺衍生物。

  DOI：

  10.1002/anie.201404620
• 作为产物：
  描述：

  benzenesulfonic acid-(N-ethyl-2,5-dimethyl-anilide) 在 盐酸 作用下， 生成 2,5-dimethyl-N-ethylaniline
  参考文献：
  名称：

  Hinsberg; Kessler, Chemische Berichte, 1905, vol. 38, p. 911

  摘要：

  DOI：

文献信息

• Non-fluorescent quencher compounds and biomolecular assays
  申请人：——

  公开号：US20030082547A1

  公开（公告）日：2003-05-01

  Bis-diazo,triaryl and aryldiazo-N-arylphenazonium quencher moieties, substituted with electron-withdrawing and electron-donating substituents which induce polarity in the delocalized aryl/diazo ring systems, are useful as labels when attached to biomolecules such as polynucleotides, nucleosides, nucleotides, and polypeptides. The quencher moieties are non-fluorescent and accept energy from fluorescent reporter labels by any energy-transfer mechanism, such as FRET. Fluorescence quencher compositions are useful in preparing quencher labelled biomolecules for various molecular biology assays based on fluorescence detection. 1

  双重重氮基、三芳基和芳基重氮-N-芳基苯酚盐猝灭基团，通过带电子吸引和电子给予取代基团引起芳基/重氮环系统极性，当连接到生物分子如多核苷酸、核苷、核苷酸和多肽时，可作为标签。这些猝灭基团是非荧光的，并通过任何能量转移机制（如FRET）从荧光报告标签吸收能量。荧光猝灭剂组合物在制备带有猝灭剂标记的生物分子，用于基于荧光检测的各种分子生物学分析中，非常有用。
• [EN] COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS<br/>[FR] POLYTHÉRAPIE POUR TRAITER UN PARAMYXOVIRUS
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2016022464A1

  公开（公告）日：2016-02-11

  Disclosed herein are a combination of compounds and methods of using the combination compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.

  本文披露了一种化合物组合以及使用该化合物组合来改善、治疗和/或预防副黏病毒感染的方法。
• [EN] MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION<br/>[FR] BENZIMIDAZOLES CONTENANT DU MORPHOLINYLE EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：TIBOTEC PHARM LTD

  公开号：WO2005058871A1

  公开（公告）日：2005-06-30

  The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C1-10alkanediyl; Rl is Ar1 or a monocyclic or bicyclic heterocycle Q is R7, pyrrolidinyl substituted with R7, piperidinyl substituted with R7 or homopiperidinyl substituted with R7; one of R2a and R3a is selected from halo, optionally mono- or polysubstituted Cl-6alkyl, optionally mono- or polysubstituted C2-6alkenyl, nitro, hydroxy, Ar2, N(R4aR4), N(R4aR4)sulfonyl, N(R4aR4b)carbonyl, C1-6alkyloxy, Ar2oxy, Ar2Cl-6alkyloxy, carboxyl, Cl-6alkyloxycarbonyl, or -C(=Z)Ar2; and the other one of R2a and R3a is hydrogen; in case R2a is different from hydrogen then R2b is hydrogen, C1-6alkyl or halogen and R3b is hydrogen; in case R3a is different from hydrogen then R3b is hydrogen, C1-6alkyl or halogen and R2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.

  本发明涉及含有对呼吸道合胞病毒复制具有抑制活性的吗啉基苯并咪唑的化合物，其具有式（I），一种前药、N-氧化物、加合盐、季铵盐、金属配合物或其立体化异构体，其中G是直键或可选择地取代的C1-10烷二基；R1是Ar1或单环或双环杂环；Q是R7，R7取代的吡咯烷基、R7取代的哌啶基或R7取代的同构异哌啶基；R2a和R3a中的一个选自卤素、可选择单取代或多取代的Cl-6烷基、可选择单取代或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4)、N(R4aR4)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2Cl-6烷氧基、羧基、Cl-6烷氧羰基或-C(=Z)Ar2；R2a和R3a中的另一个是氢；如果R2a与氢不同，则R2b是氢、C1-6烷基或卤素，R3b是氢；如果R3a与氢不同，则R3b是氢、C1-6烷基或卤素，R2b是氢。还涉及其制备以及包含这些化合物的组合物，以及其作为药物的用途。
• Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
  申请人：Bonfanti Jean-Francois

  公开号：US20070099924A1

  公开（公告）日：2007-05-03

  Aminobenzimidazoles and benzimidazoles having inhibitory activity on RSV replication and having the formula the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof, wherein G is a direct bond or C 1-10 alkanediyl optionally substituted with one or more hydroxy, C 1-6 alkyloxy, Ar 1 C 1-6 alkyloxy, C 1-6 alkylthio, Ar 1 C 1-6 alkylthio, HO(—CH 2 —CH 2 —O) n —, C 1-6 alkyloxy(—CH 2 —CH 2 —O) n — or Ar 1 C 1-6 alkyloxy(—CH 2 —CH 2 —O) n —; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle; Q is hydrogen, amino or mono- or di(C 1-4 alkyl)amino; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(═Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. Compositions containg these compounds as active ingredient and processes for preparing these compounds and compositions.

  具有RSV复制抑制活性的氨基苯并咪唑和苯并咪唑，其具有以下公式的前药，N-氧化物，加成盐，季铵盐，金属配合物和立体化学异构体形式，其中G是直接键或C1-10烷二基，可选地取代一个或多个羟基，C1-6烷氧基，Ar1C1-6烷氧基，C1-6烷基硫基，Ar1C1-6烷基硫基，HO（-CH2-CH2-O）n-，C1-6烷氧基（-CH2-CH2-O）n-或Ar1C1-6烷氧基（-CH2-CH2-O）n-; R1是Ar1或单环或双环杂环; Q是氢，氨基或单或双（C1-4烷基）氨基之一; R2a和R3a中的一个选自卤素，可选择单或多取代的C1-6烷基，可选择单或多取代的C2-6烯基，硝基，羟基，Ar2，N（R4aR4b），N（R4aR4b）磺酰基，N（R4aR4b）羰基，C1-6烷氧基，Ar2氧基，Ar2C1-6烷氧基，羧基，C1-6烷氧羰基或-C（═Z）Ar2; R2a和R3a中的另一个是氢; 在R2a不同于氢的情况下，R2b是氢，C1-6烷基或卤素，而R3b是氢; 在R3a不同于氢的情况下，R3b是氢，C1-6烷基或卤素，而R2b是氢。含有这些化合物作为活性成分的组合物以及制备这些化合物和组合物的过程。
• MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
  申请人：Bonfanti Jean-Francois

  公开号：US20080280881A1

  公开（公告）日：2008-11-13

  The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C 1-10 alkanediyl; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle Q is R 7 , pyrrolidinyl substituted with R 7 , piperidinyl substituted with R 7 or homopiperidinyl substituted with R 7 ; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(=Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.

  本发明涉及含有吗啡啉基的苯并咪唑，具有对呼吸道合胞病毒复制的抑制活性，其具有以下式子: 其中G为直接键或可选取代的C1-10烷二基；R1为Ar1或单环或双环杂环；Q为R7、用R7取代的吡咯烷基、用R7取代的哌啶基或用R7取代的同型哌啶基；R2a和R3a中的一个选自卤素、可选单或多取代的C1-6烷基、可选单或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4b)、N(R4aR4b)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2C1-6烷氧基、羧基、C1-6烷氧羰基或—C(=Z)Ar2；而R2a和R3a中的另一个为氢；若R2a不为氢，则R2b为氢、C1-6烷基或卤素，而R3b为氢；若R3a不为氢，则R3b为氢、C1-6烷基或卤素，而R2b为氢。 此外，本发明还涉及其制备方法和包含这些化合物的组合物，以及其作为药物的用途。